pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-383 |
Genomic Coordinates | chr8: 14853438 - 14853510 |
Synonyms | MIRN383, hsa-mir-383, MIR383 |
Description | Homo sapiens miR-383 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-383-5p | |||||||||||||||||||||||||||||||||||||||||||||
Sequence | 7| AGAUCAGAAGGUGAUUGUGGCU |28 | |||||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | GRAP2 | ||||||||||||||||||||
Synonyms | GADS, GRAP-2, GRB2L, GRBLG, GRID, GRPL, GrbX, Grf40, Mona, P38 | ||||||||||||||||||||
Description | GRB2-related adaptor protein 2 | ||||||||||||||||||||
Transcript | NM_004810 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on GRAP2 | |||||||||||||||||||||
3'UTR of GRAP2 (miRNA target sites are highlighted) |
>GRAP2|NM_004810|3'UTR 1 ACTCTTCAGGGGACAGAAGCTTTTTGTCTGGAGCTGCCCACAAGAAAGAGGGCAAGGAAAAAAGGCTGGACTCCATGACT 81 ATATATACATACATCTATCTACATCTGCCTGTGTACACACACAACTTTTTATACTAGTAATTTATTGGCAATTGGGCTGG 161 TAATTAGTTGATGCAAAAGGGAACTCAGGTGGAGAATAATATTGACACTTGCTTTTCTGCCCCCCTCAGGGGTGTGTGGA 241 AGGCAGTGGGGGAGTTGGGAGGGGGGCAGGGAAATGAAATGGAGTTTTGTCCTGGCCTTCAGCTGTCACTGCTTCCTCCT 321 TGTCTTGGGAATTTTCACGGAGAACAGCTAAGCAGAGACCACACCTCGGCACTGGACACAGAACAACAGGGTGGGGTTGA 401 ACTTGGTGGGGCACGTTCTAGCTGACCTGCAAGCCCCGCTCACCTGGAGGGCTTGCAGAGCAGCTCTCCTCCTGTTCTCC 481 AAGGGGTGGGCACTGTTGCATTAGGAATTAAGGTGCAGCCCAGTGCTGCGGGCAGCCAAGCGAGTCTGAGCGGGGATGTG 561 AAGGCAGGACGGGGTTGGAGAGACCCTGCCTGTGCAAGGCTGGCCTCCTAGTCAACACCTAGCTGAGACATTCATCTCTG 641 TTCAAATTAATATTCCTTGGGTCTTTCAAATGAATGTTTCAATGTGAGGAGCGAAGTACTGGGAAATCGAGGGATTTTCC 721 ACAATCCCCAAGCAGCTTACTCAGTGGAACCTCTGTTTCCCCAGCTATGAAGGAAATAGCATCCTACATTCCGTAAAGTG 801 CTTGAAGAAGCTCTAGCTGAGAATGCTGAATTTTACAGTCATTGTTTTATGGTTACAAGGGTATGTCTTCAGGGCTCTGT 881 TCATTTTCCCTCTTGATTTTCTCTTTTGAAGATGCCTTGCCCAGTGGCATGGAAAGAAGCCCACTTGATGATAGGAGCCT 961 GACTATGAATTGATTGACTAAACATGACCCCAGGTGGAAGCTGGCTTTGACACCAGCTTCCTGTTCAGTCTGACCACTGC 1041 TGTCCTCCTGCTGCCCAAGAGTTGCACCTGGAGCAAGGAACCCCACCATGGCTGTCGCTCTCCATCCCATCACGCTAGAA 1121 TCATGTGTCCAAGGGCTCACTCTGGAGGTGCACAGCACAGGTCAGCCTGGCCAGGGGCGAAGGAGACAGTAGAGAGGAAG 1201 CTCAGGGCCTTAGGGGAGGCCGGGTGCAAACCCGTTCTGCACCAAGTGCACTCGGAGTTTGTGGGTATGGGTGTGTACCC 1281 CTGCAGGTGTGCACATGTGTGCTTGCACGCACATATTTGTGCACTCCTGTGTGTATACATGTGTGCTTGTGTATGCATAT 1361 GTGTGCATTCCTGCATGTGTGGACATGTGCGTGCATGCATCTGTGTGTCTGTGTGTGTGCTGAGACAGGAAAGGGGGTGA 1441 AAGTGTTGGTGAGGGAGCCTGGAAGTTTTCTCTTCCCCAACCTCTCTTGCTCTAAGGAGGGATGGGGTTGGGGGCAGCCG 1521 TTATTGAAGGTGATCGGAGAAGAAAGATTTTCTGACTCAGAAGTGACTGCCAGTGTAGCACAAGCAGTGTCCCTTGTGAC 1601 TGTGATTCTACAGTTCTCTGATCCTCATGTTTCCTTTAGAGGAAAGAGGAAAAAAGGAACTCTGTGGTGGGTATTGGGAG 1681 GGAAAAGAAAATAGCCTGGTGGAGGCAGGAGGGAGTCGAGTGTGAGTAAGGAGCACCTGCAGCTTTTGGAAGTGAAAGCA 1761 GAGAGAGGGAAAGGTAGCTAAGACATCCAGGAGGATCAAGGGGCAGCGTGAGAGGCACAGGGGGAGGAAAGGGAGAGGGT 1841 GAGTGGGGCCAGGGAAGAGAACGGTGTGGAGTTGGTGGGCAGATGGTGCAGGAGGAGGGCTGGGCAGTGGGGAGAGGAAG 1921 AATCAGAGCAGAGAAACCGCTGCTGCGGAAGGCAGGGAGCAAAGAAGCATAAGGAAAAGAACAGGAGAAAGAACAAAGGC 2001 AGAGAAGACCTCCTCAGCTATTTTGGTGCTAGGTAATGTGAAATGCTGCAGTAAATAAAAGCCATAAGTAATGTTTGATT 2081 TTACAGTATTTACAAACCATATGCTTTAAACAGCCCACAAACTCCATCCAGTTGTCTGATGATGTGGGAGGACCAGCTCT 2161 AGTTAGACGGAGGTATGTGATTCGATTCTGGTGGAGACTTTGTGCCTTGAAAGGCTTCTCAGGAAAGCAGTAATAAAACA 2241 AAGTGTCCTTGTTTGGCC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | C8166 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462572 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | C8166 / C8166 NL4-3 |
Location of target site | ENST00000344138.4 | 3UTR | UCUACAGUUCUCUGAUC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
96 hsa-miR-383-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT004443 | VEGFA | vascular endothelial growth factor A | 5 | 2 | ||||||||
MIRT006137 | DIO1 | iodothyronine deiodinase 1 | 3 | 1 | ||||||||
MIRT006535 | IRF1 | interferon regulatory factor 1 | 3 | 1 | ||||||||
MIRT007246 | IGF1R | insulin like growth factor 1 receptor | 1 | 1 | ||||||||
MIRT007305 | PRDX3 | peroxiredoxin 3 | 1 | 1 | ||||||||
MIRT054359 | CCND1 | cyclin D1 | 4 | 2 | ||||||||
MIRT057087 | DDIT4 | DNA damage inducible transcript 4 | 2 | 2 | ||||||||
MIRT086536 | HSPE1-MOB4 | HSPE1-MOB4 readthrough | 2 | 2 | ||||||||
MIRT086544 | MOB4 | MOB family member 4, phocein | 2 | 2 | ||||||||
MIRT438194 | PPP1R10 | protein phosphatase 1 regulatory subunit 10 | 3 | 1 | ||||||||
MIRT448282 | ZMYM2 | zinc finger MYM-type containing 2 | 2 | 2 | ||||||||
MIRT451601 | TRPM7 | transient receptor potential cation channel subfamily M member 7 | 2 | 2 | ||||||||
MIRT453387 | RHD | Rh blood group D antigen | 2 | 2 | ||||||||
MIRT458521 | C5orf22 | chromosome 5 open reading frame 22 | 2 | 2 | ||||||||
MIRT459720 | SGK494 | uncharacterized serine/threonine-protein kinase SgK494 | 2 | 2 | ||||||||
MIRT461491 | KIAA1009 | centrosomal protein 162 | 1 | 1 | ||||||||
MIRT463261 | ZIC5 | Zic family member 5 | 2 | 2 | ||||||||
MIRT464237 | VCP | valosin containing protein | 2 | 2 | ||||||||
MIRT465320 | TRAF5 | TNF receptor associated factor 5 | 2 | 2 | ||||||||
MIRT465774 | TMOD3 | tropomodulin 3 | 2 | 2 | ||||||||
MIRT467879 | SLC22A23 | solute carrier family 22 member 23 | 2 | 2 | ||||||||
MIRT469636 | RAD21 | RAD21 cohesin complex component | 2 | 6 | ||||||||
MIRT472041 | NPAT | nuclear protein, coactivator of histone transcription | 2 | 2 | ||||||||
MIRT476568 | GABARAPL1 | GABA type A receptor associated protein like 1 | 2 | 2 | ||||||||
MIRT478586 | CTDSPL2 | CTD small phosphatase like 2 | 2 | 2 | ||||||||
MIRT478870 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT482202 | AHR | aryl hydrocarbon receptor | 2 | 2 | ||||||||
MIRT484237 | IER2 | immediate early response 2 | 2 | 2 | ||||||||
MIRT487480 | NRF1 | nuclear respiratory factor 1 | 2 | 6 | ||||||||
MIRT493746 | GRAP2 | GRB2-related adaptor protein 2 | 2 | 2 | ||||||||
MIRT496836 | ZNF460 | zinc finger protein 460 | 2 | 2 | ||||||||
MIRT497234 | APOL2 | apolipoprotein L2 | 2 | 2 | ||||||||
MIRT499424 | PLCG2 | phospholipase C gamma 2 | 2 | 9 | ||||||||
MIRT500598 | UBN2 | ubinuclein 2 | 2 | 10 | ||||||||
MIRT502859 | CHEK2 | checkpoint kinase 2 | 2 | 6 | ||||||||
MIRT507727 | CLIC4 | chloride intracellular channel 4 | 2 | 4 | ||||||||
MIRT510509 | YOD1 | YOD1 deubiquitinase | 2 | 6 | ||||||||
MIRT511901 | FNBP1L | formin binding protein 1 like | 2 | 6 | ||||||||
MIRT514393 | CLUAP1 | clusterin associated protein 1 | 2 | 2 | ||||||||
MIRT520180 | WBP2 | WW domain binding protein 2 | 2 | 4 | ||||||||
MIRT531214 | PLA2G4D | phospholipase A2 group IVD | 2 | 2 | ||||||||
MIRT532846 | ZNF699 | zinc finger protein 699 | 2 | 2 | ||||||||
MIRT533461 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT539263 | ANKRD44 | ankyrin repeat domain 44 | 2 | 2 | ||||||||
MIRT539380 | ADSS | adenylosuccinate synthase | 2 | 6 | ||||||||
MIRT548129 | GAS1 | growth arrest specific 1 | 2 | 2 | ||||||||
MIRT550662 | ZFP37 | ZFP37 zinc finger protein | 2 | 2 | ||||||||
MIRT551499 | CENPN | centromere protein N | 2 | 2 | ||||||||
MIRT553778 | TAF13 | TATA-box binding protein associated factor 13 | 2 | 2 | ||||||||
MIRT554376 | SFPQ | splicing factor proline and glutamine rich | 2 | 2 | ||||||||
MIRT555821 | PCDH11Y | protocadherin 11 Y-linked | 2 | 4 | ||||||||
MIRT557558 | GOSR1 | golgi SNAP receptor complex member 1 | 2 | 2 | ||||||||
MIRT557694 | GATA6 | GATA binding protein 6 | 2 | 2 | ||||||||
MIRT561383 | TWF1 | twinfilin actin binding protein 1 | 2 | 2 | ||||||||
MIRT561414 | TSN | translin | 2 | 2 | ||||||||
MIRT561867 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT567383 | GTPBP3 | GTP binding protein 3, mitochondrial | 2 | 2 | ||||||||
MIRT569272 | PCDH11X | protocadherin 11 X-linked | 2 | 2 | ||||||||
MIRT569556 | UNC119B | unc-119 lipid binding chaperone B | 2 | 2 | ||||||||
MIRT569760 | RIMBP3C | RIMS binding protein 3C | 2 | 5 | ||||||||
MIRT573387 | GGA2 | golgi associated, gamma adaptin ear containing, ARF binding protein 2 | 2 | 2 | ||||||||
MIRT573456 | RPL41 | ribosomal protein L41 | 2 | 2 | ||||||||
MIRT573968 | DDX21 | DExD-box helicase 21 | 2 | 2 | ||||||||
MIRT574163 | ATG10 | autophagy related 10 | 2 | 2 | ||||||||
MIRT574659 | KLHL15 | kelch like family member 15 | 2 | 2 | ||||||||
MIRT574907 | Plcg2 | phospholipase C, gamma 2 | 2 | 6 | ||||||||
MIRT607496 | HEBP2 | heme binding protein 2 | 2 | 2 | ||||||||
MIRT612840 | KCNJ12 | potassium voltage-gated channel subfamily J member 12 | 2 | 4 | ||||||||
MIRT613962 | TMEM59 | transmembrane protein 59 | 2 | 2 | ||||||||
MIRT621125 | PCNXL2 | pecanex homolog 2 | 2 | 2 | ||||||||
MIRT625216 | SH3TC2 | SH3 domain and tetratricopeptide repeats 2 | 2 | 2 | ||||||||
MIRT643337 | MICA | MHC class I polypeptide-related sequence A | 2 | 2 | ||||||||
MIRT646342 | CLIC6 | chloride intracellular channel 6 | 2 | 2 | ||||||||
MIRT647361 | WDR5B | WD repeat domain 5B | 2 | 2 | ||||||||
MIRT650308 | SLC35E2 | solute carrier family 35 member E2 | 2 | 2 | ||||||||
MIRT651372 | ZBTB21 | zinc finger and BTB domain containing 21 | 2 | 2 | ||||||||
MIRT655301 | PEAR1 | platelet endothelial aggregation receptor 1 | 2 | 2 | ||||||||
MIRT681918 | SLC11A2 | solute carrier family 11 member 2 | 2 | 2 | ||||||||
MIRT684165 | ALDH1B1 | aldehyde dehydrogenase 1 family member B1 | 2 | 2 | ||||||||
MIRT688053 | GLUL | glutamate-ammonia ligase | 2 | 2 | ||||||||
MIRT690210 | C5orf45 | MRN complex interacting protein | 2 | 2 | ||||||||
MIRT691024 | CRTC3 | CREB regulated transcription coactivator 3 | 2 | 2 | ||||||||
MIRT697699 | WAC | WW domain containing adaptor with coiled-coil | 2 | 2 | ||||||||
MIRT698201 | TMEM30A | transmembrane protein 30A | 2 | 2 | ||||||||
MIRT698857 | SRSF2 | serine and arginine rich splicing factor 2 | 2 | 2 | ||||||||
MIRT702292 | LDHA | lactate dehydrogenase A | 4 | 2 | ||||||||
MIRT703341 | GDPD5 | glycerophosphodiester phosphodiesterase domain containing 5 | 2 | 2 | ||||||||
MIRT704082 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | 2 | 2 | ||||||||
MIRT713729 | SUCO | SUN domain containing ossification factor | 2 | 2 | ||||||||
MIRT719487 | RBM27 | RNA binding motif protein 27 | 2 | 2 | ||||||||
MIRT722080 | SMC2 | structural maintenance of chromosomes 2 | 2 | 2 | ||||||||
MIRT724102 | TMEM199 | transmembrane protein 199 | 2 | 2 | ||||||||
MIRT725124 | SYNRG | synergin gamma | 2 | 2 | ||||||||
MIRT725601 | CAPN6 | calpain 6 | 2 | 2 | ||||||||
MIRT737186 | RBM3 | RNA binding motif (RNP1, RRM) protein 3 | 4 | 0 | ||||||||
MIRT755379 | NOS3 | nitric oxide synthase 3 | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|